Sorbent Therapeutics Secures $21,800,000 Series B Funding

  • Feed Type
  • Date
    9/13/2010
  • Company Name
    Sorbent Therapeutics
  • Mailing Address
    750 East Bunker Court Vernon Hills, IL 60061
  • Company Description
    Sorbent Therapeutics is a biopharmaceutical company focused on the development of adaptable non-absorbed polymeric drugs to satisfy unmet clinical needs in large markets such as End Stage Renal Disease (ESRD), Congestive Heart Failure (CHF), Chronic Kidney Disease (CKD), and Hypertension.
  • Website
    http://www.sorbentrx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $21,800,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Sorbent will use the capital to advance the clinical development of its lead drug candidate CLP-1001 for patients with sodium and fluid overload or risk for hyperkalemia in renal and cardiovascular diseases, such as End Stage Renal Disease and Congestive Heart Failure.
  • M&A Terms
  • Venture Investor
    AgeChem Venture Fund
  • Venture Investor
    CMEA Ventures
  • Venture Investor
    Sofinnova Ventures
  • Venture Investor
    Dow Venture Capital
  • Venture Investor
    ARCH Venture Partners

By posting a comment, you agree to our terms and conditions.